This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Antonescu, C. R. Articles by Besmer, P. Search for Related Content PubMed PubMed Citation Articles by Antonescu, C. R. Articles by Besmer, P.

Gene Expression in Gastrointestinal Stromal Tumors Is Distinguished by KIT Genotype and Anatomic Site

Departments of ¹ Pathology, ² Biostatistics and Epidemiology, ³ Surgery, and ⁴ Medicine, Memorial Sloan-Kettering Cancer Center, and ⁵ Molecular Biology, ⁶ Computational Biology Center, and ⁷ Developmental Biology Programs, Sloan-Kettering Institute, New York, New York

ABSTRACT

Purpose: Gastrointestinal stromal tumors (GISTs) are specific KIT expressing and KIT-signaling driven mesenchymal tumors of the human digestive tract, many of which have KIT-activating mutations. Previous studies have found a relatively homogeneous gene expression profile in GIST, as compared with other histological types of sarcomas. Transcriptional heterogeneity within clinically or molecularly defined subsets of GISTs has not been previously reported. We tested the hypothesis that the gene expression profile in GISTs might be related to KIT genotype and possibly to other clinicopathological factors.

Experimental Design: An HG-U133A Affymetrix chip (22,000 genes) platform was used to determine the variability of gene expression in 28 KIT-expressing GIST samples from 24 patients. A control group of six intra-abdominal leiomyosarcomas was also included for comparison. Statistical analyses (t tests) were performed to identify discriminatory gene lists among various GIST subgroups. The levels of expression of various GIST subsets were also linked to a modified version of the growth factor/KIT signaling pathway to analyze differences at various steps in signal transduction.

Results: Genes involved in KIT signaling were differentially expressed among wild-type and mutant GISTs. High gene expression of potential drug targets, such as VEGF, MCSF, and BCL2 in the wild-type group, and Mesothelin in exon 9 GISTs were found. There was a striking difference in gene expression between stomach and small bowel GISTs. This finding was validated in four separate tumors, two gastric and two intestinal, from a patient with familial GIST with a germ-line KIT W557R substitution.

Conclusions: GISTs have heterogeneous gene expression depending on KIT genotype and tumor location, which is seen at both the genomic level and the KIT signaling pathway in particular. These findings may explain their variable clinical behavior and response to therapy.

This article has been cited by other articles:

				S. Romeo, M. Debiec-Rychter, M. Van Glabbeke, H. Van Paassen, P. Comite, R. Van Eijk, J. Oosting, J. Verweij, P. Terrier, U. Schneider, et al. Cell Cycle/Apoptosis Molecule Expression Correlates with Imatinib Response in Patients with Advanced Gastrointestinal Stromal Tumors Clin. Cancer Res., June 15, 2009; 15(12): 4191 - 4198. [Abstract] [Full Text] [PDF]

				J. O. Prior, M. Montemurro, M.-V. Orcurto, O. Michielin, F. Luthi, J. Benhattar, L. Guillou, V. Elsig, R. Stupp, A. B. Delaloye, et al. Early Prediction of Response to Sunitinib After Imatinib Failure by 18F-Fluorodeoxyglucose Positron Emission Tomography in Patients With Gastrointestinal Stromal Tumor J. Clin. Oncol., January 20, 2009; 27(3): 439 - 445. [Abstract] [Full Text] [PDF]

				C.-F. Li, W.-W. Huang, J.-M. Wu, S.-C. Yu, T.-H. Hu, Y.-H. Uen, Y.-F. Tian, C.-N. Lin, D. Lu, F.-M. Fang, et al. Heat Shock Protein 90 Overexpression Independently Predicts Inferior Disease-Free Survival with Differential Expression of the {alpha} and {beta} Isoforms in Gastrointestinal Stromal Tumors Clin. Cancer Res., December 1, 2008; 14(23): 7822 - 7831. [Abstract] [Full Text] [PDF]

				U. Yamaguchi, R. Nakayama, K. Honda, H. Ichikawa, T. Hasegawa, M. Shitashige, M. Ono, A. Shoji, T. Sakuma, H. Kuwabara, et al. Distinct Gene Expression-Defined Classes of Gastrointestinal Stromal Tumor J. Clin. Oncol., September 1, 2008; 26(25): 4100 - 4108. [Abstract] [Full Text] [PDF]

				N. P. Agaram, M. P. Laquaglia, B. Ustun, T. Guo, G. C. Wong, N. D. Socci, R. G. Maki, R. P. DeMatteo, P. Besmer, and C. R. Antonescu Molecular Characterization of Pediatric Gastrointestinal Stromal Tumors Clin. Cancer Res., May 15, 2008; 14(10): 3204 - 3215. [Abstract] [Full Text] [PDF]

				Y. Suehara, T. Kondo, K. Seki, T. Shibata, K. Fujii, M. Gotoh, T. Hasegawa, Y. Shimada, M. Sasako, T. Shimoda, et al. Pfetin as a Prognostic Biomarker of Gastrointestinal Stromal Tumors Revealed by Proteomics Clin. Cancer Res., March 15, 2008; 14(6): 1707 - 1717. [Abstract] [Full Text] [PDF]

				I. Hassan, Y. N. You, R. Shyyan, E. J. Dozois, T. C. Smyrk, S. H. Okuno, C. D. Schleck, D. O. Hodge, and J. H. Donohue Surgically Managed Gastrointestinal Stromal Tumors: A Comparative and Prognostic Analysis Ann. Surg. Oncol., January 1, 2008; 15(1): 52 - 59. [Abstract] [Full Text] [PDF]

				S. Sleijfer, E. Wiemer, C. Seynaeve, and J. Verweij Improved Insight into Resistance Mechanisms to Imatinib in Gastrointestinal Stromal Tumors: A Basis for Novel Approaches and Individualization of Treatment Oncologist, June 1, 2007; 12(6): 719 - 726. [Abstract] [Full Text] [PDF]

				E. A. Perez, J. C. Gutierrez, F. L. Moffat Jr, D. Franceschi, A. S. Livingstone, S. A. Spector, J. U. Levi, D. Sleeman, and L. G. Koniaris Retroperitoneal and Truncal Sarcomas: Prognosis Depends Upon Type Not Location Ann. Surg. Oncol., March 1, 2007; 14(3): 1114 - 1122. [Abstract] [Full Text] [PDF]

				J. S. Gold, S. M. van der Zwan, M. Gonen, R. G. Maki, S. Singer, M. F. Brennan, C. R. Antonescu, and R. P. De Matteo Outcome of Metastatic GIST in the Era before Tyrosine Kinase Inhibitors Ann. Surg. Oncol., January 1, 2007; 14(1): 134 - 142. [Abstract] [Full Text] [PDF]

				N. P. Agaram, P. Besmer, G. C. Wong, T. Guo, N. D. Socci, R. G. Maki, D. DeSantis, M. F. Brennan, S. Singer, R. P. DeMatteo, et al. Pathologic and Molecular Heterogeneity in Imatinib-Stable or Imatinib-Responsive Gastrointestinal Stromal Tumors Clin. Cancer Res., January 1, 2007; 13(1): 170 - 181. [Abstract] [Full Text] [PDF]

				L Tornillo and L M Terracciano An update on molecular genetics of gastrointestinal stromal tumours. J. Clin. Pathol., June 1, 2006; 59(6): 557 - 563. [Abstract] [Full Text] [PDF]

				N. Theou, S. Gil, A. Devocelle, C. Julie, A. Lavergne-Slove, A. Beauchet, P. Callard, R. Farinotti, A. Le Cesne, A. Lemoine, et al. Multidrug Resistance Proteins in Gastrointestinal Stromal Tumors: Site-Dependent Expression and Initial Response to Imatinib Clin. Cancer Res., November 1, 2005; 11(21): 7593 - 7598. [Abstract] [Full Text] [PDF]

				F. Haller, B. Gunawan, A. von Heydebreck, S. Schwager, H.-J. Schulten, J. Wolf-Salgo, C. Langer, G. Ramadori, H. Sultmann, and L. Fuzesi Prognostic Role of E2F1 and Members of the CDKN2A Network in Gastrointestinal Stromal Tumors Clin. Cancer Res., September 15, 2005; 11(18): 6589 - 6597. [Abstract] [Full Text] [PDF]